WuXi STA completes acquisition of its first European facility

WuXi STA's newly purchased Couvet facility
The purchase of BMS's Couvet, Switzerland facility adds commercial-scale production capacity for capsule and tablet dosage forms
Since announcing plans to buy Bristol Myers Squibb's (BMS) drug product manufacturing facility in Couvet, Switzerland earlier this year, WuXi STA has now completed the acquisition.
The site, which represents the first facility in Europe for WuXi STA, provides tablet and capsule manufacturing and packaging capabilities.
Its enhanced supply of global drug product and greater access to the European market and beyond will provide customers with more flexibility.
The company has said that combining the resources of the Couvet site with its other facilities will better support customers' long-term needs globally as they bring existing and new commercial manufacturing projects from their pipelines to the facility with the capability and capacity to supply drug products to major global markets.
Through this transaction, the CDMO has increased its global presence to eight R&D and manufacturing sites across Asia, North America and Europe, including the recently announced new manufacturing campus in Middletown, Delaware, US.
BMS has said that although the divestiture is part of its ongoing evolution of its manufacturing network to support its product portfolio, Switzerland remains an important strategic location for the company.

Related News
-
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio -
News Sharp seeks greater foothold in Chinese market through ClinsChain partnership
Sharp hopes teaming up with clinical service provider ClinsChain will open the door to the Chinese market -
News GSK spins off consumer arm Haleon in biggest European listing for a decade
Haleon becomes the world’s biggest consumer health business, but debuted with a lower-than-expected valuation -
News SIGA reports $28M worth of new orders for monkeypox antiviral
The company has seen a sharp uptick in orders for its oral treatment as monkeypox cases rise globally -
News New CPHI report looks at CDMO outsourcing and partner selection
In The Future of Outsourcing - Strategies for Partner Selection, experts from across the pharma industry look at current trends impacting the contract services landscape and gauge the merits and drawbacks of the most common outsourcing strategies ... -
News CureVac files patent infringement lawsuit against BioNTech over mRNA technology
Company is seeking ‘fair compensation’ for alleged infringement of intellectual property rights relating to the use of mRNA tech to create the Pfizer-BioNTech COVID-19 vaccine
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance